These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22395694)

  • 21. Repeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response.
    Heydarchi B; Center RJ; Gonelli C; Muller B; Mackenzie C; Khoury G; Lichtfuss M; Rawlin G; Purcell DF
    PLoS One; 2016; 11(6):e0157353. PubMed ID: 27300145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progress in HIV vaccine development.
    Hsu DC; O'Connell RJ
    Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Making it to manufacturing. The potential success of broadly neutralizing monoclonal antibodies for HIV prevention, treatment, and possibly even a cure could come at a cost.
    Dumiak M
    IAVI Rep; 2014; 18(2):4-7, 17. PubMed ID: 25105201
    [No Abstract]   [Full Text] [Related]  

  • 24. Neutralizing antibodies and control of HIV: moves and countermoves.
    Hessell AJ; Haigwood NL
    Curr HIV/AIDS Rep; 2012 Mar; 9(1):64-72. PubMed ID: 22203469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The RV144 Thai HIV vaccine trial.
    Plotkin SA
    Hum Vaccin; 2010 Feb; 6(2):159. PubMed ID: 20431337
    [No Abstract]   [Full Text] [Related]  

  • 26. Opening Fronts in HIV Vaccine Development: Tracking the development of broadly neutralizing antibodies.
    Gruell H; Klein F
    Nat Med; 2014 May; 20(5):478-9. PubMed ID: 24804756
    [No Abstract]   [Full Text] [Related]  

  • 27. Moving ahead an HIV vaccine: use both arms to beat HIV.
    Walker BD; Ahmed R; Plotkin S
    Nat Med; 2011 Oct; 17(10):1194-5. PubMed ID: 21988996
    [No Abstract]   [Full Text] [Related]  

  • 28. HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure.
    Kwong PD; Mascola JR
    Immunity; 2018 May; 48(5):855-871. PubMed ID: 29768174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
    Sadanand S; Suscovich TJ; Alter G
    Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infectious disease. An enterprising time for HIV vaccine research.
    Cohen J
    Science; 2012 Sep; 337(6101):1446. PubMed ID: 22997300
    [No Abstract]   [Full Text] [Related]  

  • 31. The 2017 Keystone Symposium on HIV Vaccines.
    Cottrell CA; Ward AB
    Hum Vaccin Immunother; 2017 Oct; 13(10):2348-2351. PubMed ID: 28786733
    [No Abstract]   [Full Text] [Related]  

  • 32. Broadly Neutralizing Antibody-Guided Carbohydrate-Based HIV Vaccine Design: Challenges and Opportunities.
    Liu CC; Zheng XJ; Ye XS
    ChemMedChem; 2016 Feb; 11(4):357-62. PubMed ID: 26762799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector.
    Bresk CA; Hofer T; Wilmschen S; Krismer M; Beierfuß A; Effantin G; Weissenhorn W; Hogan MJ; Jordan APO; Gelman RS; Montefiori DC; Liao HX; Schmitz JE; Haynes BF; von Laer D; Kimpel J
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30769947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Q&A: Françoise Barré-Sinoussi. HIV adversary.
    Barré-Sinoussi F; Gomez-Touriño I
    Nature; 2014 Oct; 514(7522):S8-9. PubMed ID: 25317595
    [No Abstract]   [Full Text] [Related]  

  • 35. INFECTIOUS DISEASES. Designer proteins produce potent HIV defense.
    Cohen J
    Science; 2015 Jun; 348(6241):1297. PubMed ID: 26089490
    [No Abstract]   [Full Text] [Related]  

  • 36. Current world literature.
    Curr Opin HIV AIDS; 2009 Sep; 4(5):453-7. PubMed ID: 20046137
    [No Abstract]   [Full Text] [Related]  

  • 37. PUBLIC HEALTH. Toward an HIV vaccine: A scientific journey.
    Fauci AS; Marston HD
    Science; 2015 Jul; 349(6246):386-7. PubMed ID: 26206922
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers
    Ozorowski G; Cupo A; Golabek M; LoPiccolo M; Ketas TA; Cavallary M; Cottrell CA; Klasse PJ; Ward AB; Moore JP
    J Virol; 2018 Jul; 92(13):. PubMed ID: 29669838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire.
    Parsons MS; Rouleau D; Routy JP; LeBlanc R; Grant MD; Bernard NF
    AIDS; 2011 Jun; 25(10):1249-64. PubMed ID: 21516028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.
    Jardine JG; Ota T; Sok D; Pauthner M; Kulp DW; Kalyuzhniy O; Skog PD; Thinnes TC; Bhullar D; Briney B; Menis S; Jones M; Kubitz M; Spencer S; Adachi Y; Burton DR; Schief WR; Nemazee D
    Science; 2015 Jul; 349(6244):156-61. PubMed ID: 26089355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.